ABSTRACT: Vitamin B 12 , or cobalamin (Cbl), is an essential nutrient. Acquisition, transport, and cellular internalization of Cbl are dependent on specific binding proteins and associated receptors. The circulating transport protein transcobalamin (TC) promotes cellular uptake via binding to specific receptors such as CD320, a receptor upregulated in several cancer cell lines. In this study, we report the successful synthesis of 89 Zirconium-labeled Cbl that was derivatized with desferrioxamine ( 89
■ INTRODUCTION
Vitamin B 12 (cobalamin, Cbl) is a critical nutrient that is physiologically required to maintain cell growth and differentiation. 1−4 Cbl is involved in the biosynthesis of nucleic acids, lipids, and proteins, and its deficiency leads to a reduction in functional methionine synthase and metabolism of methylmalonic acid in humans, leading to megaloblastic anemia and/ or various neurological disorders. 1−4 Cbl gains entry into cells upon binding to transport proteins and subsequent receptor mediated transport. Cbl in blood is bound to the transport protein transcobalamin (TC) (holo-TC), which, in turn, is recognized by specific receptors such as CD320. 1−4 Upregulation of CD320 receptors has been reported in several malignancies including breast, prostate, thyroid, cervical, colorectal, and stomach cancers. 5 The important role of Cbl in cellular proliferation and the upregulation of CD320 in tumor cells has made Cbl uptake an attractive candidate for tumor imaging, mainly using singlephoton emission computed tomography with 99m Technetiumor III Indium-labeled Cbl. 6−13 One Cbl-positron emission tomography (PET) imaging agent, labeled with 64 Cu (t 1/2 ∼ 12.7 h), has also been reported. 14 Herein, the utility of Cbl as a vector was explored for delivering the PET radionuclide 89 Zr (t 1/2 ∼ 3.27 days). We hypothesized that 89 Zr would (1) retain the sensitivity of PET imaging and (2) provide a longer visualization window by providing a greater signal-to-noise ratio compared with prior tracers reported, allowing for an improved tumor targeting and imaging. Following radiosynthesis, we evaluated the in vitro uptake and in vivo pharmacokinetics of the CD320-positive MDA-MB-453 breast cancer in athymic nude mice.
■ RESULTS
Synthesis of Cbl-Desferrioxamine (Cbl-DFO). Cbldesferrioxamine (Cbl-DFO) was synthesized by forming a carbamate linkage between the 5′-hydroxyl of deoxyribose moiety in Cbl and the amine group of DFO (Scheme 1, Figure S1 ). 15 Cbl was activated using 1,1′-carbonyl-di-(1,2,4-triazole) (CDT), followed by the addition of DFO, which links through the primary amine. Purification and characterization confirmed that the conjugate was of ≥97% purity ( Figures S2−S4 Zr-Cbl) using a previously established protocol (Scheme 1). 16 A radiolabeling efficiency of ∼97% was determined by instant thin-layer chromatography (iTLC, Figure S5a ). The specific activity of the tracer was determined by titrating 89 Zr 4+ and Cbl at different mole ratios with an 
ACS Omega
Article achieved optimum specific activity of 250 ± 20 mCi/μmol (mean ± standard deviation, n = 3).
In Vitro Stability of 89 Zr-Cbl. Stability of the tracer was analyzed by incubating 89 Zr-Cbl in saline and in human serum at 37°C. Bound versus unbound radio metal was analyzed at 0, 4, 24, and 48 h after incubation using iTLC (Figure 1a,b) . The intact tracer was located closer to the origin (40−80 mm), whereas unbound tracer was found at 100−140 mm. After 48 h of incubation, free 89 Zr was <1% in both saline and serum. TC Binding Studies. Mouse TC binding of 91 Zr-Cbl was studied by radiometric chase assay using 57 Co-labeled Cbl employing a previously described design. 17 (Figure 1c) , indicating that the modification of Zr-Cbl did not compromise binding to TC. The same results were obtained for binding to human intrinsic factor (data not shown).
In Vitro Uptake. An internalization assay was performed to test the uptake of 89 Zr-Cbl on CD320 receptor cell line MDA-MB-453 at 4 and 37°C (Figure 1d) Table S1 ) and all of the %ID/g values were reported as mean ± standard deviation.
■ DISCUSSION
In this proof-of-concept study, we report the successful production of a Cbl-derived 89 Zr tracer suitable for use in PET studies. Studies on nude mice bearing a human breast cancer cell tumor allow us to demonstrate the use of the tracer for PET visualization of the tumor.
In agreement with previous data, 17, 18 we found that 91 Zr-Cbl bound to mouse TC in a manner comparable to that of CN-Cbl ( Figure 1c) . Next, an in vitro assay was performed in the breast cancer cell line MDA-MB-453 to demonstrate a specific uptake of 89 Zr-Cbl. 19 We demonstrated a greater than 4-fold uptake of 89 Zr-Cbl at 37°C versus 4°C; blocking with 200-fold excess unlabeled Cbl had a similar reduced uptake (Figure 1d) . These results support the idea that the targeting properties of 89 Zr-Cbl in MDA-MB-453 cells rely on a Cbl-dependent internalization mechanism, likely through the CD320 receptor.
In vivo imaging with 89 Zr-Cbl showed an uptake in MDA-MB-453 tumors with 1.42 ± 0.48 of %ID/g, whereas ex vivo tissue distribution studies showed a tumor uptake of 5.11 ± 1.33 %ID/g at 4 h p.i. (Figures 2 and 3) . Notable uptake was also observed in the liver and kidneys with 4.27 ± 0.51 and 8.92 ± 1.45 %ID/g at 4 h p.i., respectively (Figure 2c ). An in vivo block using 200-fold excess of unradiolabeled Cbl showed a significantly reduced uptake (p < 0.001) of the tracer, indicating that the in vivo tumor initialization is Cbl dependent, supported in the in vitro internalization assay. Muscle-to-tumor ratio showed that the maximum tumor-to-background ratio was achieved at 4 h p.i.
To compare the uptake values with those described in the literature, the biodistribution data will be used for a more accurate comparative analysis for the rest of the discussion. Tumor uptake persisted throughout the 4−48 h imaging period without a significant change (5.
The tumor uptake achieved in our model is comparable to that of the other Cbl-based tracers reported thus far.
6−14 Ikotun et al. investigated the tumor uptake of 64 Cu-labeled Cbl in pancreatic, ovarian, murine melanoma, and colorectal tumor models, with the highest %ID/g being 4.84 ± 0.32 at 6 h p.i. in the colorectal tumor models.
14 In the melanoma model, the tumor uptake was highest (3.43 ± 0.87 %ID/g) at 1 h, which decreased to 2.64 ± 0.10 %ID/g after 24 h, whereas 89 Zr-Cbl had a higher accumulation and did not show a significant decrease in tumor accumulation over 4−48 h, p > 0. 1. One of the limitations of our 89
Zr-Cbl tracer is the observed kidney uptake (94.42 ± 4.27 %ID/g at 4 h), a problem across all of the Cbl tracers to date. Renal processing is the most prominent route for Cbl accumulation/storage and/or reabsorption and is driven by megalin, a known TC-Cbl receptor expressed in kidney proximal tubuli. 20, 21 In addition, this is the first positively charged PET tracer reported, the effect of which is unknown. An overall positive charge on the Cbl (as 89 Zr-Cbl conjugate), or indeed simply the result of modification of the β-axial position, may affect the Cbl cellular processing across tissues, as has been shown previously for two forms with varying α-ligands (OH-Cbl and CN-Cbl) Cbl species, and warrants further investigation.
12,22−24
89 Zr-Cbl shows feasibility as a PET tracer to identify MDA-MB-453 tumors in vivo. The longer window for PET imaging allowed for reduced uptake in the kidneys, a problem to date in Cbl radiotracers, while still maintaining a moderate tumor uptake over 48 h p.i. This tracer is promising since, to our knowledge, tumor uptake is the highest reported to date for a B12 based PET probe.
■ CONCLUSIONS
We have successfully developed and evaluated the first 89 Zrlabeled Cbl tracer as a viable tool for visualizing TC-mediated Cbl uptake into a CD320 positive tumor. 89 Zr-Cbl displayed retained tumor uptake up to 48 h p.i., allowing for a longer imaging window. Our data paves the road for future studies to understand the kinetics of Cbl transport and to study the use as a tool for visualizing tumors capable of accumulating Cbl.
■ EXPERIMENTAL METHODS
General. Reagents listed below were purchased and used without further manipulations: dimethyl sulfoxide (DMSO, 99%, Sigma), vitamin B 12 (Cbl, ≥98%, Sigma), 1,1′-carbonyl-di-(1,2,4-triazole) (CDT, ≥90%, Fluka), and acetonitrile (MeCN, 99.8%, Pharmaco-Aaper). Compounds were confirmed to be
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Article >96% pure by high-performance liquid chromatography (HPLC), proton nuclear magnetic resonance ( 1 H NMR), and/or inductively coupled plasma.
Proton nuclear magnetic resonance ( 1 H NMR) was performed using 400 MHz Bruker spectrometer with the residual solvent peak as an internal standard. Electrospray ionization (ESI) mass spectrometry analyses were carried out on a Shimadzu LCMS-8100. Breast cancer cells (MDA-MB-453) were obtained from the American Type Culture Collection. Charcoal stripped fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM) were purchased from Sigma and KD medicals, respectively. Penicillin− streptomycin solution with 10 000 units of penicillin and 10 mg/mL streptomycin in 0.9% NaCl was obtained from Corning.
Analysis of the radiotracer was performed using instant thinlayer chromatography (iTLC, Eckert & Ziegler Mini Scan) with an ethylenediaminetetraacetic acid (EDTA) (50 mM) mobile phase.
Synthesis of Cbl-DFO. Cbl-DFO was synthesized through the activation of the 5′-ribose-hydroxyl group with CDT. CDT (34 mg, 0.261 mmol, 7.2 equiv) was added with cyano-Cbl (50 mg, 0.0368 mmol, 1 equiv) in anhydrous DMSO (3 mL) at 40°C for 2 h. DFO (208 mg, 0.313 mmol, 7.4 equiv) was added to the reaction mixture and mixed overnight. Purification of Cbl-DFO was done using reversed-phase (RP)-HPLC (Agilent 1200) with a C18 column (Agilent Eclipse XDB-C18 5 μm, 4.6 mm × 150 mm) at a flow rate of 1 mL/min. Detection was done using a UV−vis detector at 360 nm. RP-HPLC method: . 89 Zr-Radiochemistry. Optimum conditions for radiolabeling of Cbl-DFO were tested by titrating with 89 Zr and analyzing the incubated solution using iTLC. Optimum labeling activity was found to be 250 ± 20 mCi/μmol (9250 ± 740 MBq/ micromole). Approximately 1 mCi (37 MBq) of 89 Zr(C 2 O 4 ) 2 (3D Imaging, LLC) was diluted with 0.9% saline and the pH was adjusted to 7−7.5 by adding 1 M Na 2 CO 3 . A solution of Cbl-DFO (0.004 μmol, 10.8 μg) was added to the pH-adjusted 89 Zr solution and incubated for 20 min at ambient temperature (Scheme 1). Radiolabeling efficiency of >97% was determined by iTLC using silica iTLC strips and EDTA mobile phase ( Figure S5a) . The identity of the tracer was characterized via matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) analysis using Cbl-DFO labeled with cold Zr 4+ Figure S5b) . In Vitro Stability of 89 Zr-Cbl. Stability of 89 Zr-Cbl was tested by incubating the tracer (200 μCi, 7.4 MBq, 100 μL) in saline (0.9% NaCl) and 50% (1:1 serum/saline) human serum (Sigma) at 37°C, and the solutions were analyzed at 0, 4, 24, and 48 h intervals using iTLC (Eckert & Ziegler Mini Scan).
Mouse TC Binding to 91 Zr-Cbl. Nonradioactive 91 Zr-Cbl was synthesized for TC binding studies by reacting Cbl-DFO with 91 ZrCl 4 as described above. The conjugate was characterized by ESI-MS (data not shown). Mouse TC binding of 91 Zr-Cbl was confirmed by radiometric chase assay using 57 Co-labeled Cbl and compared with free Cbl (cyanocobalamin) employing a previously described protocol. 17 Mouse TC was derived as previously described. 25 In Vitro Uptake. Modified internalization assay was performed. MDA-MB-453 cells were cultured in Cbl-free media (DMEM with 10% charcoal stripped FBS) and plated in six-well plates. Each well contained 200 000 cells plated and incubated overnight. To each well, 89 Zr-Cbl (0.1 μCi, 3.7 KBq, 0.4 pmol of Cbl per well) was added. For the blocking experiment, unmodified Cbl was added (40 pmol per well). Plates were incubated for 1, 4, and 24 h intervals at either 37 or 4°C. At the end of each time point, wells were serially washed with phosphate-buffered saline (1×), acid (1 mM acetic acid and 1 mM glycine), and base (1 M NaOH, 1 mL, 5 min). Each wash was collected and measured for bound activity using a γ counter (Perking Elmer 2480 WIZARD). Control wells were trypsinized and counted using a cell counter (Contessa II). 
■ ABBREVIATIONS
Cbl, vitamin B12 (cyanocobalamin); DFO, desferrioxamine; TC, transcobalamin; CD320, holo-transcobalamin receptor; 89 Zr, 89-Zirconium isotope; PET, positron emission tomography; FBS, fetal bovine serum; iTLC, instant thin-layer chromatography; MALDI-MSI, matrix-assisted laser desorption ionization mass spectrometry imaging; %ID/g, percent injected dose per gram; DMEM, Dulbecco's modified Eagle's medium
